Zelira and Emyria join hands for insomnia observational study
Zelira (ASX:ZLD) and Emyria (formally Emerald Clinics) have partnered to conduct an observational study of Zelira’s insomnia medication, Zenovil™.
The data collected from patients recruited through Emyria’s clinics will include details regarding diagnosis and co-morbidities, associated medications, dosing and efficacy. This data will help better inform Zelira on further clinical development and eventual product registration.
This follows the recent launch of the product in Australia through the Special Access Scheme and the conclusion of their Phase IIa clinical study indicating Zenivol™ is safe and effective for the treatment of chronic insomnia.
Zelira’s Managing Director, Richard Hopkins, said “Australia’s commitment to developing a highly regulated market for prescription cannabis medicines means this country is a global leader in collection of high-quality real-world data relating to patients treated with medicinal cannabis. This information will also inform the design of future clinical trials, reduce the risks and costs of development and accelerate the path to regulatory approval.”
Patients who are interested in taking part in this study should contact Emyria through their website – www.emeraldclinics.com.au.